Pmh21 the Cost-Effectiveness of Risperidone Long-Acting Injectable in Sweden

Long-acting risperidone of value in schizophrenia

“…1 Risperidone LA would be associated with greater health benefits ** than both olanzapine and haloperidol (3.72 vs 3.68 and 3.57 QALYs per patient, respectively), as well as cost savings ** of €360 and €5860 per patient, respectively. 1 Risperidone LA would be associated with greater health benefits ** than both olanzapine and haloperidol (3.72 vs 3.68 and 3.57 QALYs per patient, respectively), as well as cost savings ** of €360 and €5860 per patient, respectively.…”